July 7, 2021
MSD’s PD-1 inhibitor Keytruda (pembrolizumab) continued to haul in the largest sales in the Japanese pharma market in June, after regaining the top-selling crown in the previous month, according to a monthly snapshot report released by Encise. Keytruda racked up...read more